Extra Alirocumab in Addition to Statin Therapy in Symptomatic IntraCranial Atherosclerotic Stenosis ----a Pilot Study

Sponsor
The First Affiliated Hospital with Nanjing Medical University
Study ID
NCT06052020
Status
Unknown

Conditions

  • Intracranial Atherosclerotic Stenosis
  • Stroke

Eligibility Criteria

Sex
ALL
Age
30 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Alirocumab — DRUG
    alirocumab (75 mg every 2 weeks)
  • Atorvastatin — DRUG
    Atorvastatin 20-40mg

Study Details

The primary goal of the trial is to investigate whether the lipid lowering strategy using Alirocumab plus statin could cause more changes from baseline in intracranial atherosclerotic plaque and hemodynamic features during 6 months of follow-up, in patients with recent stroke/transient ischemic attack (TIA) caused by intracranial artery stenosis.

Key Dates

Start date
Sep 15, 2023
Status verified
Sep 2023
Primary completion
Sep 15, 2024
Completion
Sep 30, 2024

Study Design

Enrollment
50 participants (estimated)

Arms

  • Arm: Alirocumab added to statin therapy
    Alirocumab (75 mg every 2 weeks for 6 months) added to statin (Atorvastatin 20-40mg). Anti-platelet aggregation and risk factor management.

Primary Outcome Measure

Plaque burden (PB) [ Time Frame: This will be assessed at 6 months after recruitment. ]

Central Contacts

Related Studies